Cj. Xian et al., PRODUCTION OF A HUMAN EPIDERMAL GROWTH-FACTOR FUSION PROTEIN AND ITS DEGRADATION IN RAT GASTROINTESTINAL FLUSHINGS, Journal of molecular endocrinology, 16(1), 1996, pp. 89-97
This study describes the biosynthesis of a human epidermal growth fact
or fusion protein, Long EGF, that has a 53 amino acid extension peptid
e derived from the 46 N-terminal amino acids of porcine GH. The approa
ch allowed the production of Long EGF at high efficiency due to the ex
pression of the fusion protein in high yield as inclusion bodies in Es
cherichia coli. Long EGF had a slightly lower potency compared with na
tive EGF in a range of assays, including binding to anti-EGF antibodie
s or the EGF receptor, stimulation of Balb/3T3 fibroblast and rat inte
stinal epithelial cell growth, as well as counteracting the inhibition
of mink lung epithelial cell proliferation by transforming growth fac
tor-beta 1. Degradation of Long EGF and native EGF was compared in gas
trointestinal flushings as an indication of whether the EGF domain of
the fusion protein would be protected from proteolytic cleavage and be
useful as a trophic agent in the gut. Incubation with flushings from
the stomach or jejunum of raps caused rapid cleavage of the extension
peptide, releasing native EGF. A C-terminal truncation of Arg(53) in t
he stomach and a removal of the C-terminal pentapeptide ((49)Trp-Trp-G
lu-Leu-Arg(53)) in the small bowel was demonstrated by N-terminal sequ
encing and mass spectrometry. The degradation patterns were reflected
by changes in migration of products on SDS-PAGE and in subsequent bind
ing activities to the EGF receptor and anti-EGF antibodies. The data s
how that a human EGF fusion protein can be produced efficiently in a b
acterial expression system and that it retains biological activity in
vitro. Although the extension peptide was rapidly cleaved from Long EG
F in both stomach and small bowel producing similar biological activit
y to native EGF, it could not prevent subsequent degradation of the EG
F domain. Other strategies are being investigated to develop an effect
ive oral form of EGF that resists digestion by proteases in the gastro
intestinal tract.